13 healthcare companies reach $1B valuations this year

Thirteen healthcare companies have reached $1 billion in valuation this year––an especially notable achievement as the U.S. economy approaches a recession and investors pull back.

Business Insider reported on the 13 companies, underlying the decline in digital health investments this year. Digital-health startups raked in $6 billion in the first quarter of 2022, compared to $7.3 billion raised in the fourth quarter of 2021, Insider reported. Despite the decline, funding is still elevated above pre-pandemic levels, underscoring the huge interest in digital health among investors. 

News of the sky-high valuations also comes as healthcare is still evolving to meet the demands of the COVID-19 pandemic. As workforces and hospital and health system resources are stretched, telehealth has seen increased demand since the start of the pandemic––and many healthcare organizations have launched new virtual health programs.

 

Here are the 13 healthcare companies that made Insider’s list:

  • NexHealth - $1 billion valuation
  • Wheel - $1.02 billion valuation
  • Omada Health - $1.03 billion valuation
  • IntelyCare - $1.1 billion valuation
  • Viz.ai - $1.2 billion valuation
  • Biofourmis - $1.3 billion valuation
  • Clipboard Health - $1.3 billion valuation 
  • Clarify Health - $1.5 billion valuation
  • Athelas - $1.56 billion valuation
  • Transcarent - $1.62 billion valuation
  • BostonGene - $2.15 billion valuation
  • Oura Health - $2.55 billion valuation
  • Somatus - $2.56 billion valuation

Click the link below for the full story:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.

Philips is recalling the software associated with its Mobile Cardiac Outpatient Telemetry devices after certain high-risk ECG events were never routed to trained cardiology technicians as intended. The issue, which lasted for two years, has been linked to more than 100 injuries.